Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Posts 20-Percent Revenue Increase in Q4

NEW YORK, March 8 (GenomeWeb News) - Stratagene said today that its revenues for the fourth quarter grew 20 percent to $22.8 million, compared with $18.9 million in the fourth quarter of 2003. The company said that $5.6 million was related to Stratagene's acquisition of Hycor in June 2004.


The La Jolla, Calif.-based company spent approximately $2.7 million on research and development in the fourth quarter of 2004, a slight increase from the approximately $2.3 million it spent on R&D in Q4 2003.


Stratagene also said net income surged to $1.9 million, or $.08 per diluted share, from $237,000, or $.02 per diluted share in the year-ago period.


As of Dec. 31, 2004, Strategene had cash, cash equivalents, and marketable securities totaling $5.7 million, and total assets of $80.2 million.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.